2415545
Project Grant
Overview
Grant Description
Sbir phase I: Engineered cell lines with activated proteasomes for increased biomanufacturing efficiency -the broader impact of this small business innovation research (SBIR) phase I project will be to reduce the costs associated with the biomanufacturer of advanced therapies by making their manufacture more efficient. This project seeks to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines currently used in the manufacture of biologics, gene therapies, and vaccines.
Achievement of this project?s objectives could enhance the health and welfare of Americans by making advanced therapies more economically accessible. As the population ages, the prevalence of debilitating diseases like Alzheimer's and cancer is on the rise. This project could make the solutions to these issues more affordable and effective, significantly impacting the quality of life of Americans.
In addition, this project could help revolutionize treatment for rare genetic disorders by overcoming the current hurdles of high manufacturing costs, thereby broadening access to these vital treatments. The proposed project seeks to build on initial data showing that enhancement of the cellular proteasome has an unexpected and counterintuitive effect on protein production in cells.
The aims will be to demonstrate that this technology can be applied to cells commonly used in the manufacture of advanced therapies and that it can enhance the production of protein types relevant to human health such as gene therapy vectors and biologic drugs. Successful completion of this project will also provide new insights into the function of cells used in biomanufacturing and potentially enable further innovation in this area to ease this bottleneck on the production of advanced therapies.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria. Subawards are not planned for this award.
Achievement of this project?s objectives could enhance the health and welfare of Americans by making advanced therapies more economically accessible. As the population ages, the prevalence of debilitating diseases like Alzheimer's and cancer is on the rise. This project could make the solutions to these issues more affordable and effective, significantly impacting the quality of life of Americans.
In addition, this project could help revolutionize treatment for rare genetic disorders by overcoming the current hurdles of high manufacturing costs, thereby broadening access to these vital treatments. The proposed project seeks to build on initial data showing that enhancement of the cellular proteasome has an unexpected and counterintuitive effect on protein production in cells.
The aims will be to demonstrate that this technology can be applied to cells commonly used in the manufacture of advanced therapies and that it can enhance the production of protein types relevant to human health such as gene therapy vectors and biologic drugs. Successful completion of this project will also provide new insights into the function of cells used in biomanufacturing and potentially enable further innovation in this area to ease this bottleneck on the production of advanced therapies.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria. Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Durham,
North Carolina
27712-9543
United States
Geographic Scope
Single Zip Code
Tectaria Bio was awarded
Project Grant 2415545
worth $275,000
from National Science Foundation in July 2024 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 9 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Engineered Cell Lines with Activated Proteasomes for Increased Biomanufacturing Efficiency
Abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to reduce the costs associated with the biomanufacturer of advanced therapies by making their manufacture more efficient. This project seeks to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines currently used in the manufacture of biologics, gene therapies, and vaccines. Achievement of this project’s objectives could enhance the health and welfare of Americans by making advanced therapies more economically accessible. As the population ages, the prevalence of debilitating diseases like Alzheimer's and cancer is on the rise. This project could make the solutions to these issues more affordable and effective, significantly impacting the quality of life of Americans. In addition, this project could help revolutionize treatment for rare genetic disorders by overcoming the current hurdles of high manufacturing costs, thereby broadening access to these vital treatments.
The proposed project seeks to build on initial data showing that enhancement of the cellular proteasome has an unexpected and counterintuitive effect on protein production in cells. The aims will be to demonstrate that this technology can be applied to cells commonly used in the manufacture of advanced therapies and that it can enhance the production of protein types relevant to human health such as gene therapy vectors and biologic drugs. Successful completion of this project will also provide new insights into the function of cells used in biomanufacturing and potentially enable further innovation in this area to ease this bottleneck on the production of advanced therapies.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BT
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 7/8/24
Period of Performance
7/1/24
Start Date
4/30/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2415545
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
Z2RZB8TWNLZ8
Awardee CAGE
9RFL1
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Modified: 7/8/24